Sorafenib
Core Binding Factor Acute Myeloid Leukemia
Nanfang Hospital, Southern Medical UniversitySmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 81/ 100
Competitive context
8 Active assets in the Core Binding Factor Acute Myeloid Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Daunorubicin National Cancer Institute (NCI) | Phase 2 | B |
Cytosin-Arabinosid National Cancer Institute (NCI) | Phase 2 | B |
Dasatinib National Cancer Institute (NCI) | Phase 2 | B |
Venetoclax National Cancer Institute (NCI) | Phase 2 | CCC |
Azacitidine Children's Hospital of Soochow University | Phase 2 | CCC |
View all 10 →
Same molecule, other indications
Sorafenib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →